287 related articles for article (PubMed ID: 37435267)
1. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV.
Mahale PR; Patel BS; Kasmani N
Cureus; 2023 Jun; 15(6):e40139. PubMed ID: 37435267
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Li J; Chen D; Wen Z; Du Y; Huang Z; Zhong H; Wang Y; Yin S
Medicine (Baltimore); 2022 Oct; 101(42):e31100. PubMed ID: 36281149
[TBL] [Abstract][Full Text] [Related]
4. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
[TBL] [Abstract][Full Text] [Related]
5. Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia.
Eifa BA; Ketema W
AIDS Res Treat; 2022; 2022():2965325. PubMed ID: 35603131
[TBL] [Abstract][Full Text] [Related]
6. Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study.
Ayal MA; Berha AB
HIV AIDS (Auckl); 2023; 15():173-190. PubMed ID: 37139483
[TBL] [Abstract][Full Text] [Related]
7. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria.
Echefu SN; Udosen JE; Akwiwu EC; Akpotuzor JO; Obeagu EI
Medicine (Baltimore); 2023 Nov; 102(47):e35910. PubMed ID: 38013350
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine
Sorsa A
Open Med Inform J; 2018; 12():11-18. PubMed ID: 29875890
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre.
Isah A; Chukwu PO; Abba A; Igboeli NU; Ebere A; Omotola OF; Alozie FA; Ekwunife OI; Adibe MO
Afr Health Sci; 2023 Mar; 23(1):157-169. PubMed ID: 37545946
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir.
Meireles MV; Pascom ARP; Duarte EC; McFarland W
AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
Rutherford GW; Horvath H
PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
[TBL] [Abstract][Full Text] [Related]
16. Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection.
Chan P; Yoon B; Colby D; Kroon E; Sacdalan C; Sriplienchan S; Pinyakorn S; Ananworanich J; Valcour V; Vasan S; Hsu D; Phanuphak N; Paul R; Spudich S
Clin Infect Dis; 2023 Feb; 76(3):e718-e726. PubMed ID: 35687498
[TBL] [Abstract][Full Text] [Related]
17. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J
HIV Med; 2024 Mar; ():. PubMed ID: 38520085
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Jiang J; Xu X; Guo W; Su J; Huang J; Liang B; Chen H; Zang N; Liao Y; Ye L; Liang H
AIDS Res Ther; 2016; 13(1):30. PubMed ID: 27617024
[TBL] [Abstract][Full Text] [Related]
19. Virologic Response Following a Switch to Dolutegravir-based Regimen in People Living with HIV/AIDS at a Tertiary Care Center in Nepal.
Tamrakar R; Tamrakar D
Kathmandu Univ Med J (KUMJ); 2022; 20(80):438-442. PubMed ID: 37795720
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
Radford M; Parks DC; Ferrante S; Punekar Y
AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
